Exposure‐response relationships in patients with HER2‐positive metastatic breast cancer and other solid tumors treated with trastuzumab deruxtecan
O Yin, H Iwata, CC Lin, K Tamura… - Clinical …, 2021 - Wiley Online Library
Trastuzumab deruxtecan (T‐DXd) is a HER2‐targeting antibody‐drug conjugate composed
of a novel enzyme‐cleavable linker and membrane‐permeable topoisomerase I inhibitor …
of a novel enzyme‐cleavable linker and membrane‐permeable topoisomerase I inhibitor …
Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.
2501 Background: DS-8201a is a HER2-targeted antibody drug conjugate with novel
topoisomerase I inhibitor payload and linker technology. Methods: This ongoing phase 1 …
topoisomerase I inhibitor payload and linker technology. Methods: This ongoing phase 1 …
Population pharmacokinetics of trastuzumab deruxtecan in patients with HER2‐positive breast cancer and other solid tumors
O Yin, Y Xiong, S Endo, K Yoshihara… - Clinical …, 2021 - Wiley Online Library
Trastuzumab deruxtecan (DS‐8201) is a human epidermal growth factor receptor 2 (HER2)–
targeting antibody–drug conjugate with a novel enzyme‐cleavable linker, a topoisomerase I …
targeting antibody–drug conjugate with a novel enzyme‐cleavable linker, a topoisomerase I …
Clinical practices and institutional protocols on prophylaxis, monitoring, and management of selected adverse events associated with trastuzumab deruxtecan
A Bardia, K Harnden, L Mauro, A Pennisi… - The …, 2022 - academic.oup.com
The treatment of metastatic breast cancer (mBC) has evolved significantly in the past several
years with the approval of new targeted agents. Trastuzumab deruxtecan (T-DXd), an …
years with the approval of new targeted agents. Trastuzumab deruxtecan (T-DXd), an …
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast …
Background Antibody–drug conjugates have emerged as a powerful strategy in cancer
therapy and combine the ability of monoclonal antibodies to specifically target tumour cells …
therapy and combine the ability of monoclonal antibodies to specifically target tumour cells …
Abstract PD3-06: Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer
S Modi, C Saura, T Yamashita, YH Park, SB Kim… - Cancer research, 2021 - AACR
Abstract Background Trastuzumab deruxtecan (T-DXd, DS-8201) is an antibody-drug
conjugate with a HER2 antibody, tetrapeptide-based cleavable linker, and a novel …
conjugate with a HER2 antibody, tetrapeptide-based cleavable linker, and a novel …
Trastuzumab deruxtecan for HER2-positive metastatic breast cancer: DESTINY-Breast01 subgroup analysis.
1036 Background: Trastuzumab deruxtecan (T-DXd; DS-8201) is an antibody-drug
conjugate composed of an anti-HER2 antibody, a cleavable linker, and a cytotoxic …
conjugate composed of an anti-HER2 antibody, a cleavable linker, and a cytotoxic …
Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low–expressing advanced breast cancer: results from a phase Ib study
S Modi, H Park, RK Murthy, H Iwata… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Trastuzumab deruxtecan (T-DXd, formerly DS-8201a) is a novel human
epidermal growth factor receptor 2 (HER2)-targeted antibody drug conjugate (ADC) with a …
epidermal growth factor receptor 2 (HER2)-targeted antibody drug conjugate (ADC) with a …
Trastuzumab deruxtecan: first approval
SJ Keam - Drugs, 2020 - Springer
Trastuzumab deruxtecan (ENHERTU®), a HER2-directed antibody and DNA topoisomerase
I inhibitor conjugate, is being developed for the treatment of HER2-expressing solid tumours …
I inhibitor conjugate, is being developed for the treatment of HER2-expressing solid tumours …
138O CNS metastases in HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan: DESTINY-Breast01 subgroup analyses
G Jerusalem, YH Park, T Yamashita… - Annals of …, 2020 - annalsofoncology.org
Background Trastuzumab deruxtecan (T-DXd; DS-8201) is an antibody-drug conjugate
composed of an anti-HER2 antibody, a cleavable linker and a cytotoxic topoisomerase I …
composed of an anti-HER2 antibody, a cleavable linker and a cytotoxic topoisomerase I …
相关搜索
- breast cancer trastuzumab deruxtecan
- exposure response trastuzumab deruxtecan
- breast cancer exposure response
- solid tumors trastuzumab deruxtecan
- her2 low trastuzumab deruxtecan
- breast cancer her2 low
- ds 8201a solid tumors
- breast cancer subgroup analysis
- ds 8201a trastuzumab deruxtecan
- institutional protocols trastuzumab deruxtecan
- expansion cohorts trastuzumab deruxtecan
- subgroup analyses trastuzumab deruxtecan
- clinical practices trastuzumab deruxtecan
- population pharmacokinetics trastuzumab deruxtecan
- antitumor activity trastuzumab deruxtecan
- breast cancer population pharmacokinetics